TCGA-MZ-A5BI-01A-31R-A34R-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.049543379
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.400
- INFLAMMATORY_RESPONSE+0.260
- DNA_REPAIR+0.220
- TNFA_SIGNALING_VIA_NFKB+0.210
- E2F_TARGETS+0.200
- KRAS_SIGNALING_DN+0.170
- PANCREAS_BETA_CELLS+0.170
- IL2_STAT5_SIGNALING+0.160
- IL6_JAK_STAT3_SIGNALING+0.160
- INTERFERON_GAMMA_RESPONSE+0.140
Top 10 suppressed
- TGF_BETA_SIGNALING-0.490
- PROTEIN_SECRETION-0.460
- MITOTIC_SPINDLE-0.400
- UV_RESPONSE_DN-0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.350
- MYOGENESIS-0.320
- ANDROGEN_RESPONSE-0.280
- MYC_TARGETS_V2-0.280
- MTORC1_SIGNALING-0.250
- HEME_METABOLISM-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-GM-A2DO-01A-11R-A18M-07 | — | D | 0.775 |
| 2 | TCGA-CX-A4AQ-01A-11R-A24Z-07 | — | — | 0.763 |
| 3 | MNG913 | — | — | 0.742 |
| 4 | 289b3dee-bd46-4286-8e7b-86ffb573d37e | — | — | 0.731 |
| 5 | SRR9879287 | — | cohortA1 | 0.725 |
| 6 | b03d2223-38c1-4bb3-be8b-27db05f87b66 | — | — | 0.723 |
| 7 | SRR25617834 | — | D | 0.720 |
| 8 | TCGA-E2-A1B6-01A-31R-A12P-07 | — | D | 0.718 |
| 9 | SRR1313153 | — | D | 0.707 |
| 10 | MNG88 | — | — | 0.703 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.260 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.210 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.170 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.160 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.160 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.140 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.120 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.120 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.060 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.040 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.030 | Inavolisib | — uncovered |
| COMPLEMENT | 0.020 | Inavolisib | — uncovered |